Credit Suisse’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Credit Suisse’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-9,632	Closed	-$1.27M	–	4715
2020 Q4	$1.27M	Buy	9,632 +3,775	+64%	+$334K	﹤0.01%	3157
2020 Q3	$295K	Buy	5,857 +73	+1%	+$3.28K	﹤0.01%	3660
2020 Q2	$276K	Buy	5,784 +176	+3%	+$8.19K	﹤0.01%	3619
2020 Q1	$275K	Sell	5,608 -21,184	-79%	-$1.08M	﹤0.01%	3478
2019 Q4	$1.54M	Buy	26,792 +8,683	+48%	+$430K	﹤0.01%	2823
2019 Q3	$651K	Buy	+18,109	New	+$707K	﹤0.01%	3283

Credit Suisse's EIDX Position: Q1 2021 in Review

Credit Suisse sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 9,632 shares — an estimated $1.27M sold.

Credit Suisse first reported a position in EIDX in Q3 2019 and held it in 6 quarters. The position peaked at $1.54M in Q4 2019. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Credit Suisse reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Credit Suisse sold 9,632 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.27M.
Credit Suisse first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 6 quarters.
Credit Suisse's Eidos Therapeutics, Inc. Common Stock position peaked at $1.54M in Q4 2019.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.